Intrepid, Cosmo Pharma to conduct CB-03-01 trials
CB-03-01 acts by blocking testosterone (T) and dihydrotestosterone (DHT) from binding to the receptor in the cell. The multi-center double-blind placebo controlled dose-escalating Phase II acne study will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.